Company intelligence / Profile preview

Inositec

Zurich, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Inositec is developing inositol phosphate–based small molecules against calcification disorders using its Inositune platform. Its lead compound INS-3001 is described as a cardiovascular calcification inhibitor in development for aortic valve stenosis, with available descriptions consistent with pre-clinical to early development status and no publicly reported completed clinical trials yet.[1][2][3]

Therapeutic areas: CardiovascularNephrology
Modalities: Small molecule
Industry: Biotech

Partnerships

Vifor Pharma (acquirer and strategic partner in cardiorenal space)

Beyond the preview

Go deeper on Inositec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inositec.

Explore the full profile